Zai Lab (HKG:9688) shrank its net loss in the first quarter to $48.4 million from $53.5 million in the year-ago period, a Thursday Hong Kong bourse filing said.
Loss per share stood at $0.04 for the three months, down from $0.05 in the corresponding period last year.
The biopharmaceutical company saw its revenue for the quarter rise 22% to $106.5 million from $87.1 million a year prior.
The lower loss was mainly due to product revenue growing faster than net operating expenses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.